Skip to main content

Market Overview

The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week

Share:
The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week

Biotech stocks advanced in the week ended Feb. 12, thanks to broader market strength and company-specific catalysts. Small and mid-cap earnings, multiple conference presentations, data readouts and a slew of IPOs were all part of the week's news flow.

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) received two FDA approvals during the week. Immunotherapy Libtayo, which the company co-developed with Sanofi SA (NASDAQ: SNY), got a label expansion as a treatment option for basal cell carcinoma. Regeneron also received the nod for its Evkeeza, as an adjunctive treatment option for ultra-rare cholesterol disease.

Ocugen Inc (NASDAQ: OCGN) and Kalvista Pharmaceuticals Inc (NASDAQ: KALV) were among the best performing stocks of the week. The former moved on momentum gathered on the back of a U.S. COVID-19 vaccine deal with Bharat Biotech and the news of an offering priced at a premium. Kalvista gained on a positive data readout.

Conferences

BIO CEO & Investor Digital Conference: Feb. 16-18

PDUFA Dates

The FDA is set to rule on G1 Therapeutics Inc's (NASDAQ: GTHX) new drug application for trilaciclib as a treatment option for mitigating the impact of chemotherapy in small-cell lung cancer. The PDUFA date by which the verdict has to be issued is Monday, Feb. 15.

Related Link: Pharma Stock Ideas: Why BMO Is Recommending Regeneron, Constellation

Earnings

Monday

Medpace Holdings Inc (NASDAQ: MEDP)

Tuesday

Zoetis Inc (NYSE: ZTS) (before the market open)
EXACT Sciences Corporation (NASDAQ: EXAS) (after the market close)

Wednesday

Royalty Pharma plc (NASDAQ: RPRX) (before the market open)
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (before the market open)
Blueprint Medicines Corp (NASDAQ: BPMC) (before the market open)
10X Genomics Inc (NASDAQ: TXG) (after the close)
Invitae Corp (NYSE: NVTA) (after the close)
Globus Medical Inc (NYSE: GMED) (after the close)
Shockwave Medical Inc (NASDAQ: SWAV) (after the close)
Veracyte Inc (NASDAQ: VCYT) (after the close)
Viking Therapeutics Inc (NASDAQ: VKTX) (after the close)

Thursday

West Pharmaceutical Services Inc. (NYSE: WST) (before the market open)
Syneos Health Inc (NASDAQ: SYNH) (before the market open)
Avanos Medical Inc (NYSE: AVNS) (before the market open)
Integra Lifesciences Holdings Corp (NASDAQ: IART) (before the market open)
Emergent Biosolutions Inc (NYSE: EBS) (after the close)
Quidel Corporation (NASDAQ: QDEL) (after the close)
Opko Health Inc. (NASDAQ: OPK) (after the close)

Related Link: Novavax Shares Pass The $300 Mark: Is The Rally Sustainable?

 

Related Articles (IBB)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Previews Small Cap FDA Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com